Department of gastrointestinal medical oncology: providing chemotherapy for gastrointestinal cancer based on the latest knowledge

Hidekazu Hirano / Ken Kato

2023/9/15

• Our department provides chemotherapy for gastric cancer, colorectal cancer, and rare cancers originating in the gastrointestinal tract (e.g., small bowel cancer, neuroendocrine neoplasm (NET/NEC), gastrointestinal stromal tumor (GIST), and anal canal cancer) using cutting-edge evidence. In addition to chemotherapy for inoperable or recurrent conditions, we also offer “multidisciplinary treatment” with curative intent in collaboration with departments of surgery, radiation therapy, endoscopy, radiology, and pathology.
• We are actively implementing “cancer genome medicine”. By using next-generation sequencers, the identification of genetic abnormalities in cancer can be performed for expanding drug availability. From 2019 to 2022, 191 people underwent testing, and 12 people (6%) received drug therapy based on genetic abnormalities, such as ALK-fusion and RET-fusion.”
• We are conducting clinical trials in collaboration with domestic and international institutions, aiming to establish novel drug therapy.

• Chemotherapy